Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03457493 · ClinicalTrials.gov registry record · Phase 1

The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

A Phase 1 study of Parkinson Disease, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
Phase 1
Development phase
205
Enrollment target
1
Study location

NCT03457493 is a Phase 1 study of Parkinson Disease that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 205 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03457493, a Phase 1 study of Parkinson Disease, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
Phase 1
Development phase
205 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The amount and distribution of \[18F\]DPA-714 in the brain will be correlated to clinical data acquired through the separate ongoing UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The primary objective of this study is to determine if patients with PD have higher levels of neuroinflammation than healthy controls as measured with \[18F\]DPA-714-PET/MRI.

Conditions Studied

Parkinson Disease

Interventions

  • DRUG DPA-714-PET/MRI
  • DRUG 5-year Follow-up DPA-714-PET/MRI
  • DRUG DPA-714 Metabolite Analysis

Study Locations (1)

Alabama

  • UAB Advanced Imaging Facility - Birmingham

Trial Details

FieldValue
Enrollment Target 205 participants
Start Date 2018-03-22
Est. Completion 2027-06
Phase Phase 1

Sponsor

University of Alabama at Birmingham

1,160 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03457493

The ClinicalTrials.gov registry entry for NCT03457493 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 3 interventions - of which DPA-714-PET/MRI is the first listed.

NCT03457493 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT03457493 about?

NCT03457493 is a clinical study titled "The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy". The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and...

What is the current status of trial NCT03457493?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 205 participants. The study started on 2018-03-22. Estimated completion is 2027-06.

What conditions does trial NCT03457493 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT03457493?

The interventions under investigation include: DPA-714-PET/MRI (DRUG), 5-year Follow-up DPA-714-PET/MRI (DRUG), DPA-714 Metabolite Analysis (DRUG).

Who is sponsoring clinical trial NCT03457493?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03457493 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.